Scienture Gains Coverage to 100M Lives, Targets 60% Institutional Market with 10 mg Nasal Spray
SCNX•Scienture’s REZENOPY™ nasal spray secured coverage from a large national health plan, extending potential reach to over 100 million covered lives ahead of its mid-July commercial launch. The 10 mg spray has GPO contracts with 5,000+ facilities covering ~60% of the US institutional market within a $144M naloxone sector.
1. Formulary Coverage Secured
Scienture secured formulary inclusion for REZENOPY™ 10 mg nasal spray with a large national health plan, extending potential coverage to over 100 million lives under commercial and Medicare supplemental benefits.
2. Institutional Access via GPO Agreements
Group Purchasing Organization agreements with more than 5,000 healthcare facilities grant REZENOPY™ access to roughly 60% of the US institutional naloxone market, positioning the product within hospitals, EMS providers, rehabilitation centers and other institutions.
3. Commercial Launch and Team Expansion
The company plans a mid-July commercial launch supported by an expanded sales organization that added three new representatives as part of a multi-channel strategy targeting institutional, government and commercial customers to drive broad market adoption.
